Long-lasting Immunotherapy Response in Stage IV Lung Cancer with Brain Metastasis
FOR IMMEDIATE RELEASE
2024-10-18
“In the last decade, immunotherapy agents changed the treatment landscape for Non-Small Cell Lung Cancer (NSCLC).”
BUFFALO, NY - October 18, 2024 – A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis.”
As highlighted in the abstract of this report, approximately 20% of lung cancer patients have brain metastases at diagnosis, which is associated with a worse prognosis and negatively impacts quality of life. The emergence of new systemic treatment options, such as immune checkpoint inhibitors (ICI) and targeted therapies, has changed the prognosis for stage IV lung cancer patients. However, the impact of treatment sequencing—both local and systemic—in patients with stage IV lung cancer and brain metastases remains unclear.
Researchers Mafalda Costa and Helena Magalhães from the Department of Medical Oncology, Hospital Pedro Hispano in Matosinhos, Portugal present the case of a 51-year-old man diagnosed with stage IV non-small cell lung cancer (NSCLC) and brain metastasis. After undergoing whole brain radiotherapy (WBRT), the patient achieved both intracranial and extracranial complete response following second-line treatment with an immune checkpoint inhibitor. Currently, he has an overall survival of 87 months and a progression-free survival of 73 months, maintaining an optimal quality of life.
"We hypothesized that treatment sequencing of WBRT and immunotherapy could explain this unexpected outcome.”
Continue reading: DOI: https://doi.org/10.18632/oncoscience.609
Corresponding author: Mafalda Costa - [email protected]
Keywords: cancer, lung cancer, complete response, immune checkpoint inhibitors, brain metastasis, whole-brain radiotherapy
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
Oncoscience is indexed and archived by PubMed, PubMed Central, Scopus, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact [email protected].
Oncoscience Journal Office
6666 East Quaker Str., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4